Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8334373 Nuclease resistant double-stranded ribonucleic acid

Patent 8334373 was granted and assigned to Alnylam Pharmaceuticals on December, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Alnylam Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8334373

Patent Inventor Names

Ingo Roehl0

Kallanthottathil G. Rajeev0

Muthiah Manoharan0

Philipp Hadwiger0

Tracy Stage Zimmermann0

Akin Akinc0

Hans-Peter Vornlocher0

Date of Patent

December 18, 2012

Patent Application Number

13038672

Date Filed

March 2, 2011

Patent Citations Received

‌

US Patent 12104156 Compositions and methods of treating facioscapulohumeral muscular dystrophy

‌

US Patent 11712478 Compositions and methods of treating muscle atrophy and myotonic dystrophy

‌

US Patent 11872287 Compositions and methods of treating muscle atrophy and myotonic dystrophy

‌

US Patent 11879125 GalNAc compositions for improving siRNA bioavailability

‌

US Patent 11999955 Compositions and methods of treating facioscapulohumeral muscular dystrophy

Patent Primary Examiner

‌

Jennifer Pitrak McDonald

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8334373 Nuclease resistant double-stranded ribonucleic acid

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API